Outcomes are now available out to 4 years for the prospective nonrandomized STRATO trial. Th is 10-center French study was undertaken between April 2010 and February 2011 in order to assess the effi cacy, safety, and performance of the Multilayer Flow Modulator (MFM) (Cardiatis, Isnes, Belgium) and its device delivery system in patients ineligible for surgical or endograft repair presenting with Crawford type II and III thoracoabdominal aneurysms (TAAA).1, 2 Th e MFM is an uncovered, self-expanding stent with high radial force and fl exibility constructed of braided fatigue- and corrosionresistant cobalt-alloy wire (Phynox). Th e device was designed to thrombose and stabilize the aneurysm sac while creating an organized laminar fl ow into covered branch vessels without the need for the extra steps involved in cannulation.3 Th e MFM received CE marking for peripheral artery aneurysms in 2009 and for aortic aneurysms in 2011. It was thought that the flow-diverting MFM technology could have numerous potential advantages for treating challenging TAAA — particularly type II and III TAAA that span the ostia of visceral and renal arteries — as an alternative to physician-modifi ed or commercially customized fenestrated and/or branched endografts. Th ose endovascular approaches have been associated with high costs, long manufacturing delays, extended learning curve, and outcomes including perioperative spinal cord ischemia (SCI), renal insufficiency, type I and III endoleak, and frequent need for reintervention.4-9
By contrast, the MFM is an off -the shelf device available in a wide range of sizes. While preoperative assessment of patient anatomy and pathology and evaluation of landing zones and device sizing are still important with the MFM, extensive measurements and calculations are not required regarding visceral side branch location, diameters, and angulation. Treatment with the MFM can also be less invasive, with vascular access limited to a single sheath in one femoral/brachial artery for introduction of an angiographic catheter and another sheath in the other femoral artery for introduction of the device, without the need for additional upperextremity access. Implantation of the MFM requires
30/ Remplacement combiné de l’aorte ascendante et de la valve aortique
31/ Opération de Bentall
Sociétés scientifiques
Sociétés françaises :
Société française de Chirurgie Cardiovasculaire et Thoracique, Membre titulaire élu
Collège de Chirurgie Vasculaire Collège Français de Chirurgie Thoracique et Cardiovasculaire Compagnie des experts près la cour d‘appel de Versailles , les cours administratives d‘appel de Paris et Versailles Secrétaire général adjoint de la Société Française d‘Angiologie
Sociétés étrangères :
Fellow of the European Board of Thoracic and Cardiovascular Surgery
Récompenses du Dr Claude Vaislic
Françaises :
Lauréat de la Fondation “Le pied à l‘étrier”
Lauréat de la Faculté de Médecine (Médaille d‘Or, Major 1ère année de médecine,)
Lauréat de la Faculté de Médecine (Médaille d‘Or, Major 2 ème année de médecine)
Lauréat de la Faculté de Médecine (Médaille d‘Or de thèse)
Étrangères :
Physician Recognition Award AMERICAN MEDICAL ASSOCIATION
Titres étrangers du Dr Claude Vaislic
Educational Commission for Foreign Medical Graduates, PARIS
Federal License Examination: Flex. INDIANAPOLIS,
Visa Qualification Examination: V.Q.E., NEW YORK
License médicale dans l‘état de Floride, U.S.A., no. ME 39410
Drug Enforcement Administration no. AV1456703
Advance Cardiac Life Support: AMERICAN HEART ASSOCIATION
License Médicale au Royaume Unis et inscription sur la liste de spécialistes: General Médical Council Registration no. 4475488
Fellow of the European Board of Thoracic and Cardiovascular Surgery
Titres hospitaliers du Dr Claude Vaislic
Interne des Hôpitaux
Chef de Clinique-Assistant des Hôpitaux
Attaché des Hôpitaux Chirurgie Thoracique et Cardiovasculaire
Inscrit sur la liste d‘aptitude de Praticien Hospitalier en Chirurgie Thoracique et Cardiovasculaire
